PC(procarbazine-CCNU) chemotherapy in patients with recurrent or resistant glioblastoma
- Conditions
- Not Applicable
- Registration Number
- KCT0000605
- Lead Sponsor
- The Catholic University of Korea, Incheon St. Mary's Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 52
1)Histologically or radiologically confirmed progressive or recurrent glioblastoma with methylated MGMT promoter
2)Within 6 months after or during Stupp regimen (TMZ-RT CCRT + adjuvant TMZ), or After re-treatment of cyclic TMZ, 6 months later after Stupp regimen
3)KPS = 60%
4)Age = 20 years
5)At least two weeks apart from prior surgery and prior chemotherapy
6)Adequate hematologic, liver, and renal functions
7)Unstained slides for central pathology review
8)Signed informed consent
1)maternity or pregnant
2)Prior malignancy within 5 years except for basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and carcinoma in situ of the cervix
3)Evidence of active infection within 2 weeks prior to study
4)Previous treatment with procarbazine and/or CCNU
5)Evidence of leptomeningeal metastasis
6)Unable to comply with the study protocol.
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method progression free survival
- Secondary Outcome Measures
Name Time Method survival